Interview with the Innovators

Interview with the Innovators

Video Library | August 9, 2023
This Interview with the Innovator video features breast cancer nurse navigators Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, as they discuss ovarian function suppression, how patients tolerate side effects, and educating patients on expectations of treatment.
Video Library | August 9, 2023
Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, examine fertility issues associated with ovarian function suppression and the psychosocial impact it has on young breast cancer patients.
Video Library | August 9, 2023
This Interview with the Innovator video features two breast cancer nurse navigators, Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, reviewing combination therapy with ovarian function suppression and its effects in breast cancer patients, including the importance of setting up-front expectations of treatment.
Video Library | August 9, 2023
Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, highlight the challenges with ovarian function suppression side effects patients face and explore tactics to encourage adherence to treatment.
Video Library | August 9, 2023
Gain insights from Emily Beard, RN, BSN, OCN, CBCN, breast oncology nurse navigator, in this Interview with the Innovator video on communication techniques to discuss sensitive topics with breast cancer patients including sexual health dysfunction associated with ovarian function suppression.
Video Library | August 9, 2023
In this Interview with the Innovator video, Melissa Simon, BSN, RN, OCN, ONN-CG, and Emily Beard, RN, BSN, OCN, CBCN, discuss common and expected side effects with ovarian function suppression as well as adverse side effects to monitor and report to a healthcare provider.
September 2022 Vol 13, No 9 | September 19, 2022
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The American Cancer Society estimates over 20,000 new CLL cases and over 4000 attributed deaths in 2022.
Video Library | February 15, 2022
Dr Steven Rowe continues his discussion of PYLARIFY® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.
Video Library | February 8, 2022
Dr Steven Rowe continues his discussion of PYLARIFY® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.
Video Library | February 1, 2022
Dr Steven Rowe expands on the sensitivity and specificity of PYLARIFY® (piflufolastat F 18) imaging in high-risk prostate cancer.
Page 2 of 11
Results 11 - 20 of 108

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country